[The clinical use of antilymphocyte globulin (ALG) (author's transl)].
ALG is mainly used for immunosuppressive treatment following organ transplants. Controlled clinical trials demonstrated the efficacy of ALG in kidney, bone marrow and skin transplantation. Pilot studies describe a therapeutic effect in human autoaggression. A possible therapeutic effect, however, depends upon the strict observation of the following criteria: 1. Adequate dosage (20 mg/kg and more). 2. Intravenous application. 3. Suppression of sensitization against xenogeneic globulin by induction of immunological unresponsiveness before ALG-treatment (prevention of allergic complications and increase of ALG efficacy). Previously published negative results with ALG can be explained by failure to comply with the above criteria.
D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D006736:Horses / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000517:prevention & control; D007074:Immunoglobulin G / Q000008:administration & dosage; D007165:Immunosuppression Therapy; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D012712:Serum Globulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016038:Skin Transplantation; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D012712:Serum Globulins
Die klinische Anwendung von Antilymphozytenglobulin (ALG)